Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NM

Trial Details

NCT ID

NCT04844528

Phase

PHASE2

Sponsor

University of Utah

Status

RECRUITING

Cancer Type

Melanoma

Interventions

• Nicotinamide
• Placebo

Locations (sample)

• Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

• Male or female subject aged ≥ 18 years.
• Confirmed diagnosis of CLL or small lymphocytic leukemia (SLL) per iwCLL 2018 criteria.
• History of ≥1 non-melanoma skin cancer (NMSC) diagnosed within the last 5 years
• Adequate liver function as defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →